In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression

[1]  A. Heredia,et al.  Chemokine receptors and HIV-2. , 1997, AIDS.

[2]  K. Peden,et al.  STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.

[3]  D. Ho,et al.  Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry , 1997, Journal of virology.

[4]  M. Giacca,et al.  C–C Chemokines Released by Lipopolysaccharide (LPS)-stimulated Human Macrophages Suppress HIV-1 Infection in Both Macrophages and T Cells , 1997, The Journal of experimental medicine.

[5]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[6]  A. Fauci,et al.  CD8+ T-cell-derived soluble factor(s), but not β-chemokines RANTES, MIP-1α, and MIP-1β, suppress HIV-1 replication in monocyte/macrophages , 1996 .

[7]  R. Doms,et al.  CD4-Independent Infection by HIV-2 Is Mediated by Fusin/CXCR4 , 1996, Cell.

[8]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[9]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[10]  R. Koup,et al.  Workshop Summary: Workshop on Perinatally Acquired Human Immunodeficiency Virus Infection in Long-Term Surviving Children: A Collaborative Study of Factors Contributing to Slow Disease Progression , 1996 .

[11]  A. Garzino-Demo,et al.  The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection , 1996, Nature Medicine.

[12]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[13]  J. Sodroski,et al.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.

[14]  M. Bukrinsky,et al.  Chemokines and HIV replication , 1996, Nature.

[15]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[16]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[17]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[18]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[19]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[20]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[21]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[22]  J. Albert,et al.  Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates , 1994, Journal of virology.

[23]  J. Albert,et al.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.

[24]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[25]  E. Halapi,et al.  Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[27]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[28]  J. Albert,et al.  Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. , 1991, AIDS.

[29]  R. Weiss,et al.  Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus , 1991, Virology.

[30]  J. Albert,et al.  REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION , 1986, The Lancet.

[31]  J. Sodroski,et al.  Construction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genes , 1986, Journal of virology.

[32]  N. Yamamoto,et al.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. , 1985, Science.